

# Chemotherapeutic Engineering

Collected Papers of Si-Shen Feng  
A Tribute to Shu Chien on His 82nd Birthday

edited by  
Feng Si-Shen  
Jenny Rompas  
Stanford Chong






A Tribute to Professor Shu Chien  
on His 82nd Birthday

**六院院士 世界唯一**

The only one in the world who simultaneously  
holds six Academicians: US Academy of Sciences,  
US Academy of Engineering, US Institute of  
Medicine, US Academy of Arts & Sciences,  
Chinese Academy of Sciences,  
and Academia Sinica, Taiwan

2013





# Chemotherapeutic Engineering



# Chemotherapeutic Engineering

**Collected Papers of Si-Shen Feng  
A Tribute to Shu Chien on His 82nd Birthday**

edited by  
**Feng Si-Shen  
Jenny Rompas  
Stanford Chong**

*Published by*

Pan Stanford Publishing Pte. Ltd.  
Penthouse Level, Suntec Tower 3  
8 Temasek Boulevard  
Singapore 038988

Email: [editorial@panstanford.com](mailto:editorial@panstanford.com)

Web: [www.panstanford.com](http://www.panstanford.com)

**British Library Cataloguing-in-Publication Data**

A catalogue record for this book is available from the British Library.

**Chemotherapeutic Engineering: Collected Papers of Si-Shen Feng—A Tribute to Shu Chien on His 82nd Birthday**

Copyright © 2014 Pan Stanford Publishing Pte. Ltd.

*All rights reserved. This book, or parts thereof, may not be reproduced in any form or by any means, electronic or mechanical, including photocopying, recording or any information storage and retrieval system now known or to be invented, without written permission from the publisher.*

For photocopying of material in this volume, please pay a copying fee through the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, USA. In this case permission to photocopy is not required from the publisher.

ISBN 978-981-4463-14-0 (Hardcover)

ISBN 978-981-4463-15-7 (eBook)

Printed in the USA

# Contents

*Preface*

xxxvii

## PART I INTRODUCTION

<b>1 Chemotherapeutic Engineering: Concept, Feasibility, Safety and Prospect—A Tribute to Shu Chien's on His 82nd Birthday</b>	<b>3</b>
<i>Si-Shen Feng</i>	
1.1 Introduction	3
1.2 Nanotechnologies in Chemotherapeutic Engineering	5
1.2.1 Prodrugs—Polymer–Drug Conjugation	5
1.2.2 Micelles	6
1.2.3 Liposomes	6
1.2.4 Nanoparticles of Biodegradable Polymers	6
1.2.5 Combined Nanoparticle-Vesicle Systems	7
1.3 Proof-of-Concept Experimental Results	7
1.4 Safety Issue	14
1.5 Prospect	14

## PART II CHEMOTHERAPEUTIC ENGINEERING: CONCEPTS

<b>2 Chemotherapeutic Engineering: Application and Further Development of Chemical Engineering Principles for Chemotherapy of Cancer and Other Diseases</b>	<b>21</b>
<i>Si-Shen Feng and Shu Chien</i>	
2.1 Introduction	21
2.1.1 Cancer and Cancer Chemotherapy	21
2.1.2 Problems in Chemotherapy	23
2.1.3 Chemotherapeutic Engineering	27
2.2 Nanoparticle Technology for Chemotherapy	29
2.2.1 Manufacture of Nanoparticles	31
2.2.2 Nanoparticle Characterization	35
2.2.3 In vitro Experiments	40
2.2.4 Animal Tests and Clinical Trials	43
2.3 Liposomes for Chemotherapy	45



2.4	Liposomes-in-Microspheres	47
2.5	Oral Chemotherapy	49
2.6	Blood–Brain Barrier	51
2.7	Molecular Interactions between Anticancer Drugs and Cells	52
2.8	Mathematical Modeling and Computer Simulation	54
<b>3</b>	<b>New-Concept Chemotherapy by Nanoparticles of Biodegradable Polymers: Where Are We Now?</b>	<b>81</b>
	<i>Si-Shen Feng</i>	
3.1	Copolymer Synthesis and Nanoparticle Preparation	85
3.2	Nanoparticle Characterization	86
3.3	In vitro Cellular Uptake of Nanoparticles	88
3.4	In vitro Cancer Cell Viability	90
3.5	In vivo Pharmacokinetics	92
3.6	Xenograft Model	94
3.7	Multifunctional Nanoparticles	95
3.8	Conclusions	97
3.9	Future Perspective	98
<b>4</b>	<b>Nanoparticles of Biodegradable Polymers for New-Concept Chemotherapy</b>	<b>105</b>
	<i>Si-Shen Feng</i>	
4.1	Nanoparticle Formulation and Characterization	110
4.1.1	Nanoparticle Formulation	110
4.1.2	Nanoparticle Characterization	111
4.2	In vitro Experiments	115
4.2.1	In vitro Drug Release	115
4.2.2	Cell Line Experiments	116
4.3	Animal Tests and Clinical Trials	118
4.4	Expert Opinion	120
4.5	Five-Year View	121
<b>5</b>	<b>Nanoparticles of Biodegradable Polymers for Cancer Treatment</b>	<b>129</b>
	<i>Si-Shen Feng</i>	
<b>PART III CHEMOTHERAPEUTIC ENGINEERING: FEASIBILITY</b>		
<b>6</b>	<b>Chemotherapeutic Engineering: Vitamin E TPGS-Emulsified Nanoparticles of Biodegradable Polymers Realized Sustainable Paclitaxel Chemotherapy for 168 h in vivo</b>	<b>139</b>
	<i>Si-Shen Feng, Lingyun Zhao, Zhiping Zhang, Gajadhar Bhakta, Khin Yin Win, Yuancai Dong, and Shu Chien</i>	
6.1	Introduction	139

6.2	Methods	141
6.2.1	Preparation of Nanoparticles	141
6.2.2	Nanoparticle Characterization	142
6.2.3	In vitro Cellular Uptake of Nanoparticles	142
6.2.4	In vitro Cytotoxicity	143
6.2.5	In vivo Pharmacokinetics	143
6.2.6	Xenograft Model	144
6.3	Results and Discussions	144
6.4	Conclusions	151

#### **PART IV CHEMOTHERAPEUTIC ENGINEERING: FURTHER PROOF-OF CONCEPT EXPERIMENTAL RESULTS**

<b>7</b>	<b>In vitro and in vivo Investigation on PLA-TPGS Nanoparticles for Controlled and Sustained Small Molecule Chemotherapy</b>	<b>157</b>
	<i>Zhiping Zhang, Sie Huey Lee, Chee Wee Gan, and Si-Shen Feng</i>	
7.1	Introduction	157
7.2	Materials and Methods	159
7.2.1	Materials	159
7.2.2	Synthesis of PLA-TPGS Copolymers	159
7.2.3	Preparation of Paclitaxel-Loaded PLA-TPGS Nanoparticles	160
7.2.4	Characterization of Nanoparticles	160
7.2.4.1	Particles size, surface morphology and surface chemistry	160
7.2.4.2	Drug encapsulation efficiency	160
7.2.5	In vitro Drug Release	160
7.2.6	Cellular Uptake	161
7.2.7	Animal Test	161
7.2.7.1	Pharmacokinetics and biodistribution	161
7.2.7.2	Xenograft tumor model	163
7.3	Results and Discussion	163
7.3.1	Formulation Optimization	163
7.3.2	Surface Morphology, Surface Chemistry and in vitro Drug Release	166
7.3.3	Cellular Uptake of Nanoparticles	168
7.3.4	Pharmacokinetics	169
7.3.5	Biodistribution	170
7.3.6	Xenograft Tumor Model	171
7.4	Conclusions	175
<b>8</b>	<b>In vitro and in vivo Evaluation of Methoxy Polyethylene Glycol-Polylactide Nanoparticles for Small-Molecule Drug Chemotherapy</b>	<b>179</b>
	<i>Yuancai Dong and Si-Shen Feng</i>	
8.1	Introduction	179

8.2	Materials and Methods	181
8.2.1	Materials	181
8.2.2	Preparation of Paclitaxel-Loaded MPEG-PLA NPs	181
8.2.3	Particle Size, Surface Morphology and Drug Encapsulation Efficiency	181
8.2.4	Differential Scanning Calorimetry	182
8.2.5	In vitro Drug Release	182
8.2.6	In vitro Cytotoxicity	182
8.2.7	Cellular Uptake of Fluorescent NPs	183
8.2.8	In vivo Pharmacokinetic Analysis	183
8.3	Results and Discussion	184
8.3.1	Characterization of Paclitaxel-Loaded MPEG-PLA NPs	184
8.3.2	In vitro Drug Release	185
8.3.3	DSC	185
8.3.4	Viability of MCF-7 Cells	186
8.3.5	In vitro Cellular Uptake of NPs	188
8.3.6	In vivo Pharmacokinetics Analysis	189
8.4	Conclusion	191
9	<b>The Drug Encapsulation Efficiency, in vitro Drug Release, Cellular Uptake and Cytotoxicity of Paclitaxel-Loaded Poly(Lactide)-Tocopheryl Polyethylene Glycol Succinate Nanoparticles</b>	<b>195</b>
	<i>Zhiping Zhang and Si-Shen Feng</i>	
9.1	Introduction	195
9.2	Materials and Methods	197
9.2.1	Materials	197
9.2.2	Synthesis and Characterization of PLA-TPGS Copolymers	197
9.2.3	Formulation of Paclitaxel-Loaded PLA-TPGS NPs	198
9.2.4	Characterization of NPs	198
9.2.4.1	Particle size and size distribution	198
9.2.4.2	Surface charge	198
9.2.4.3	Surface morphology	199
9.2.4.4	Drug encapsulation efficiency	199
9.2.4.5	In vitro drug release	199
9.2.5	Cell Line Experiment	199
9.2.5.1	Cell culture	199
9.2.5.2	In vitro cellular uptake of NPs	200
9.2.5.3	In vitro cell viability	200
9.3	Results and Discussion	201
9.3.1	Characterization of PLA-TPGS Copolymers	201
9.3.2	Characterization of PLA-TPGS NPs	202
9.3.2.1	Size and size distribution	202

9.3.2.2	Surface charge	202
9.3.2.3	Surface morphology	202
9.3.2.4	Drug encapsulation efficiency	203
9.3.2.5	In vitro drug release profile	204
9.3.3	Cellular Uptake of NPs	205
9.3.4	In vitro Cell Viability of Drug-Loaded NPs	208
9.4	Conclusions	210
<b>10</b>	<b>Nanoparticles of Poly(D,L-Lactide)/Methoxy Poly(Ethylene Glycol)-Poly(D,L-Lactide) Blends for Controlled Release of Paclitaxel</b>	<b>215</b>
	<i>Yuancai Dong and Si-Shen Feng</i>	
10.1	Introduction	215
10.2	Materials and Methods	217
10.2.1	Materials	217
10.2.2	Preparation of Paclitaxel-Loaded NPs	217
10.2.3	Characterization of Paclitaxel-Loaded NP	218
10.2.3.1	Size and zeta potential	218
10.2.3.2	Drug encapsulation efficiency	218
10.2.3.3	Morphology	218
10.2.3.4	Surface chemistry	218
10.2.3.5	DSC	219
10.2.3.6	In vitro drug release	219
10.3	Results and Discussion	219
10.3.1	Size, ZP, and Drug EE	219
10.3.2	Morphology	221
10.3.3	Surface Charge	221
10.3.4	DSC	223
10.3.4.1	In vitro drug release	224
10.4	Conclusions	225
<b>11</b>	<b>In vitro and in vivo Studies on Vitamin E TPGS-Emulsified Poly(D,L-Lactic-co-Glycolic Acid) Nanoparticles for Paclitaxel Formulation</b>	<b>231</b>
	<i>Khin Yin Win and Si-Shen Feng</i>	
11.1	Introduction	231
11.2	Materials and Methods	233
11.2.1	Materials	233
11.2.2	Preparation and Characterization of Nanoparticles	233
11.2.3	In vitro Cytotoxicity	234
11.2.4	In vivo Pharmacokinetics	234
11.3	Results and Discussions	235
11.3.1	Size, Surface Morphology and Zeta-Potential	235
11.3.2	Surface Chemistry	236

11.3.3	In vitro Drug Release	237
11.3.4	In vitro Cytotoxicity	237
11.3.5	In vivo Pharmacokinetics	239
11.4	Conclusion	240
<b>12</b>	<b>Nanoparticles of Poly(Lactide)/Vitamin E TPGS Copolymer for Cancer Chemotherapy: Synthesis, Formulation, Characterization and in vitro Drug Release</b>	<b>245</b>
	<i>Zhiping Zhang and Si-Shen Feng</i>	
12.1	Introduction	245
12.2	Materials and Methods	247
12.2.1	Materials	247
12.2.2	Synthesis of PLA-TPGS Copolymer	247
12.2.3	Characterization of PLA-TPGS Copolymer	247
12.2.4	Preparation of Paclitaxel-Loaded PLA-TPGS Nanoparticles	248
12.2.5	Characterization of Drug-Loaded PLA-TPGS Nanoparticles	248
12.2.5.1	Particle size analysis	248
12.2.5.2	Surface morphology	248
12.2.5.3	Surface charge	248
12.2.5.4	Drug encapsulation efficiency	248
12.2.5.5	Surface chemistry	249
12.2.5.6	In vitro drug release	249
12.3	Results and Discussion	249
12.3.1	Synthesis of PLA-TPGS Copolymer	249
12.3.2	Molecular Weight and Molecular Weight Distribution	250
12.3.3	Size, Size Distribution and Drug Encapsulation Efficiency	252
12.3.3.1	Drug encapsulation efficiency	254
12.3.3.2	Effects of polymeric matrix materials	254
12.3.3.3	Effects of mechanical mixing strength	255
12.3.4	Surface Morphology	255
12.3.5	Zeta Potential	255
12.3.6	Surface Chemistry	255
12.3.7	In vitro Drug Release	258
12.4	Conclusion	258
<b>13</b>	<b>A Novel Controlled Release Formulation for the Anticancer Drug Paclitaxel (Taxol®): PLGA Nanoparticles Containing Vitamin E TPGS</b>	<b>263</b>
	<i>L. Mu and S. S. Feng</i>	
13.1	Introduction	263

13.2	Materials and Methods	265
13.2.1	Materials	265
13.2.2	Nanoparticle Preparation	266
13.2.3	Encapsulation Efficiency	266
13.2.4	Nanoparticle Characterisation	267
13.2.4.1	Size and size distribution	267
13.2.4.2	Morphology	267
13.2.4.3	DSC analysis	267
13.2.4.4	Surface analysis	268
13.2.5	In vitro release study	268
13.3	Results and Discussions	268
13.3.1	A Novel Formulation of Nanoparticles for Controlled Release of Paclitaxel	268
13.3.2	Formulation Optimisation	270
13.3.2.1	Morphology of nanoparticles	270
13.3.2.2	Particle size and size distribution	270
13.3.2.3	Yield and encapsulation efficiency	274
13.3.3	DSC Analysis	276
13.3.4	Surface Analysis	278
13.3.5	In vitro Release	279
13.4	Conclusions	281
<b>14</b>	<b>Fabrication, Characterization and in vitro Release of Paclitaxel (Taxol®) Loaded Poly(Lactic-co-Glycolic Acid) Microspheres Prepared by Spray Drying Technique with Lipid/Cholesterol Emulsifiers</b>	<b>285</b>
	<i>L. Mu and S. S. Feng</i>	
14.1	Introduction	285
14.2	Materials and Methods	287
14.2.1	Materials	287
14.2.2	Microspheres Characterization	288
14.2.3	Encapsulation Efficiency	288
14.2.4	In vitro Release Study	289
14.3	Results and Discussion	290
14.3.1	Microsphere Preparation and Encapsulation Efficiency	290
14.3.2	Size and Morphology Characteristics of the Microspheres	290
14.3.3	DSC Analysis	293
14.3.4	Zeta Potential Analysis	295
14.3.5	In vitro Release	299
14.4	Conclusions	302

<b>15</b>	<b>Effects of Emulsifiers on the Controlled Release of Paclitaxel (Taxol®) from Nanospheres of Biodegradable Polymers</b>	<b>307</b>
	<i>Si-Shen Feng and Guofeng Huang</i>	
15.1	Introduction	307
15.2	Materials and Methods	310
15.2.1	Materials	310
15.2.2	Methods	310
	15.2.2.1 Preparation of polymeric nanospheres	310
	15.2.2.2 Particle characterization	311
	15.2.2.3 In vitro release of paclitaxel	311
	15.2.2.4 Encapsulation efficiency	312
	15.2.2.5 Extraction factor and recovery efficiency measurement	312
15.3	Results and Discussion	312
15.3.1	Effects of Various Emulsifiers	313
	15.3.1.1 Surface chemistry	313
	15.3.1.2 Surface morphology	318
	15.3.1.3 Size and encapsulation efficiency	319
	15.3.1.4 In vitro release profile	323
15.3.2	Effect of Chain Length and Chain Unsaturation of Lipids	325
	15.3.2.1 Surface chemistry	325
	15.3.2.2 Zeta potential	328
	15.3.2.3 Encapsulation efficiency and size distribution	329
15.4	Conclusions	332
<b>PART V CHEMOTHERAPEUTIC ENGINEERING: DRUG TARGETING</b>		
<b>16</b>	<b>Copolymer Technology for Advanced Nanomedicine</b>	<b>339</b>
	<i>Zhiping Zhang, Xiangliang Yang, and Si-Shen Feng</i>	
<b>17</b>	<b>A Strategy for Precision Engineering of Nanoparticles of Biodegradable Copolymers for Quantitative Control of Targeted Drug Delivery</b>	<b>347</b>
	<i>Yutao Liu, Kai Li, Bin Liu, and Si-Shen Feng</i>	
17.1	Introduction	347
17.2	Materials and Methods	351
17.2.1	Materials	351
17.2.2	Preparation of Nanoparticles	351
17.2.3	Herceptin Conjugation and Ligand Surface Density Control	352
17.2.4	Surface Chemistry Analysis	352
17.2.5	Characterization of the Nanoparticles	352
	17.2.5.1 Particle size and size distribution of the NPs	352
	17.2.5.2 Surface charge	353

17.2.5.3	Drug load	353
17.2.5.4	Particle morphology	353
17.2.6	In vitro Drug Release	353
17.2.7	Cell Culture	354
17.2.8	In vitro Cellular Uptake	354
17.2.9	In vitro Cytotoxicity	354
17.2.10	Statistical Analysis	355
17.3	Results	355
17.3.1	Preparation and Size Characterization of the NPs	355
17.3.2	Herceptin Conjugation and Surface Chemistry Analysis	355
17.3.3	Control of Ligand Surface Density on NPs Surface	356
17.3.4	Characterization of the Docetaxel-Loaded NPs: Before and After Herceptin Conjugation	359
17.3.5	Surface Morphology	360
17.3.6	In vitro Drug Release Profile	361
17.3.7	In vitro Cellular Uptake: Quantitative Study	362
17.3.8	In vitro Cellular Uptake: Confocal Microscopy Study	364
17.3.9	In vitro Cytotoxicity	366
17.4	Discussion	368
17.5	Conclusions	370
<b>18</b>	<b>Folic Acid Conjugated Nanoparticles of Mixed Lipid Monolayer Shell and Biodegradable Polymer Core for Targeted Delivery of Docetaxel</b>	<b>375</b>
	<i>Yutao Liu, Kai Li, Jie Pan, Bin Liu, and Si-Shen Feng</i>	
18.1	Introduction	375
18.2	Materials and Methods	378
18.2.1	Materials	378
18.2.2	Fabrication of the Nanoparticles	378
18.2.3	Characterization of the Nanoparticles	379
18.2.3.1	Particle size and size distribution	379
18.2.3.2	Drug encapsulation efficiency (EE)	379
18.2.3.3	Particle morphology	379
18.2.3.4	Surface charge	379
18.2.3.5	Surface chemistry	380
18.2.4	Controlled Drug Release	380
18.2.5	Cell Culture	380
18.2.6	In vitro Cellular Uptake	380
18.2.7	In vitro Cell Cytotoxicity	381
18.2.8	Statistical Analysis	381
18.3	Results and Discussion	381
18.3.1	Fabrication of the Nanoparticles	381
18.3.2	Characterization of the Nanoparticles	383



18.3.2.1	Particle size, size distribution and drug encapsulation efficiency	383
18.3.2.2	Surface morphology	384
18.3.2.3	Surface charge	384
18.3.2.4	Surface chemistry	384
18.3.3	In vitro Drug Release	385
18.3.4	In vitro Cellular Uptake	386
18.3.5	In vitro Cytotoxicity	389
18.4	Conclusions	391
<b>19</b>	<b>Quantitative Control of Targeting Effect of Anticancer Drugs Formulated by Ligand-Conjugated Nanoparticles of Biodegradable Copolymer Blend</b>	<b>395</b>
	<i>Jing Zhao, Yu Mi, Yutao Liu, and Si-Shen Feng</i>	
19.1	Introduction	395
19.2	Materials and Methods	398
19.2.1	Materials	398
19.2.2	Synthesis of PLA-TPGS and TPGS-COOH Copolymers	399
19.2.3	Preparation of Nanoparticles	399
19.2.4	Herceptin Conjugation	400
19.2.5	Particle Size	400
19.2.6	Surface Charge	400
19.2.7	Surface Morphology	400
19.2.8	Surface Chemistry	400
19.2.9	Surface Herceptin Visualization	401
19.2.10	Drug Toad	401
19.2.11	Determination of Herceptin Surface Density	401
19.2.11.1	Bradford protein assay	401
19.2.11.2	Fluorescent staining and flow cytometer analysis	401
19.2.12	Cell Culture	402
19.2.13	In vitro Cellular Uptake Study of the HER2 Conjugated NPs	402
19.2.13.1	Qualitative study: confocal microscopy	402
19.2.13.2	Quantitative study: microplate reader	402
19.2.14	In vitro Cytotoxicity	402
19.3	Results and Discussion	403
19.3.1	Characterization of PLA-TPGS/TPGS-COOH and TPGS/(TPGS-COOH+TPGS) NPs before and after Herceptin Conjugation	403
19.3.1.1	Size and size distribution	403
19.3.1.2	Surface Charge	403
19.3.1.3	Surface morphology	404

19.3.1.4	Drug load	405
19.3.1.5	Surface chemistry	406
19.3.1.6	Surface herceptin visualization	406
19.3.2	Quantification of Surface Antibody Density	407
19.3.2.1	Bradford assay	407
19.3.2.2	Fluorescent labeling and flow cytometer analysis	409
19.3.3	In vitro Cellular Uptake: Quantitative Study	411
19.3.4	In vitro Cellular Uptake: Confocal Microscopy Study	411
19.3.5	In vitro Cytotoxicity	413
19.4	Conclusion	414
<b>20</b>	<b>Trastuzumab-Functionalized Nanoparticles of Biodegradable Copolymers for Targeted Delivery of Docetaxel</b>	<b>419</b>
	<i>Bingfeng Sun and Si-Shen Feng</i>	
20.1	Materials and Methods	421
20.1.1	Synthesis of PLA-TPGS and TPGS-COOH Copolymer	422
20.1.2	Preparation of NPs	422
20.1.3	Characterization of NPs Size and Size Distribution	423
20.1.3.1	Surface charge	425
20.1.3.2	Surface morphology	425
20.1.3.3	Drug EE	425
20.1.3.4	Surface chemistry	425
20.1.3.5	SDS-PAGE	425
20.1.3.6	In vitro docetaxel-release kinetics	426
20.1.4	Cell Culture	426
20.1.5	In vitro Cellular Uptake Study Qualitative Study: CLSM	426
20.1.5.1	Quantitative study: Microplate reader analysis	427
20.1.6	In vitro Cytotoxicity	427
20.2	Results and Discussion	428
20.2.1	Physicochemical Properties of NPs Size and Size Distribution	428
20.2.1.1	Surface charge	429
20.2.1.2	Surface morphology of NPs	429
20.2.1.3	Drug EE	429
20.2.1.4	Surface chemistry	430
20.2.1.5	SDS-PAGE	431
20.2.1.6	In vitro drug release kinetics	431
20.2.2	Cellular Uptake of NPs Qualitative Study	434
20.2.2.1	Quantitative study	434
20.2.3	In vitro cytotoxicity	437
20.3	Conclusion	440

<b>21 Folate-Decorated Poly(Lactide-co-Glycolide)-Vitamin E TPGS Nanoparticles for Targeted Drug Delivery</b>	<b>447</b>
<i>Zhiping Zhang, Sie Huey Lee, and Si-Shen Feng</i>	
21.1 Introduction	447
21.2 Materials and Methods	449
21.2.1 Materials	449
21.2.2 Synthesis of DOX-PLGA-TPGS	449
21.2.3 Synthesis of TPGS-FOL	451
21.2.4 Characterization of the Synthesized Conjugates	452
21.2.5 Preparation of DOX-Loaded NPs	452
21.2.6 Characterization of the DOX-Loaded NPs	452
21.2.7 Surface Chemistry	453
21.2.8 In vitro Drug Release Kinetics	453
21.2.9 In vitro Cytotoxicity	453
21.2.10 In vitro Cellular Uptake of NPs	453
21.2.11 Statistical Analysis	454
21.3 Results and Discussion	454
21.3.1 Characterization of the Synthesized Conjugates	454
21.3.2 Characterization of DOX-Loaded NPs	455
21.3.3 Surface Chemistry	457
21.3.4 In vitro Drug Release	458
21.3.5 In vitro Cytotoxicity	458
21.3.6 In vitro Cellular Uptake of NPs	460
21.4 Conclusion	463
 <b>22 Ligand-Conjugated Nanoparticles of Biodegradable Polymers for Targeted Delivery of Imaging and Therapeutic agents to Biological Cells</b>	 <b>467</b>
<i>Yu Mi, Yutao Liu, Yajun Quo, and Si-Shen Feng</i>	
22.1 Herceptin®-Conjugated Nanocarriers for Targeted Imaging and Treatment of HER2-Positive Cancer	467
22.2 Benefit of Anti-HER2-Coated Paclitaxel-Loaded Immuno-Nanoparticles in the Treatment of Disseminated Ovarian Cancer: Therapeutic Efficacy and Biodistribution in Mice	469
22.3 Targeted Near-Infrared Quantum Dot-Loaded Micelles for Cancer Therapy and Imaging	470
22.4 Listeriolysin O Enhances Cytoplasmic Delivery by HER2-Targeting Liposomes	471
22.5 Nanoconjugation Modulates the Trafficking and Mechanism of Antibody-Induced Receptor Endocytosis	472

<b>23 Formulation of Docetaxel by Folic Acid-Conjugated D-<math>\alpha</math>-Tocopheryl Polyethylene Glycol Succinate 2000 (Vitamin E TPGS<sub>2k</sub>) Micelles for Targeted and Synergistic Chemotherapy</b>	<b>475</b>
<i>Yu Mi, Yutao Liu, and Si-Shen Feng</i>	
23.1 Introduction	475
23.2 Materials and Methods	478
23.2.1 Materials	478
23.2.2 Synthesis of TPCS <sub>2k</sub> and TPGS <sub>3350</sub> -FOL	478
23.2.3 Preparation of Micelles	479
23.2.4 Characterization of TPGS <sub>2k</sub> Micelles	479
23.2.4.1 Micelle size and size distribution	479
23.2.4.2 Drug encapsulation efficiency	479
23.2.4.3 Determination of the critical micelle concentration	481
23.2.5 Controlled Drug Release	481
23.2.6 Cell Culture	481
23.2.7 In vitro Cellular Uptake	481
23.2.8 In vitro Cell Cytotoxicity	482
23.3 Results and Discussion	482
23.3.1 Characterization of TPGS <sub>2k</sub> Micelles and FA Micelles	482
23.3.1.1 Micelle size and size distribution	482
23.3.1.2 Drug encapsulation efficiency	483
23.3.1.3 CMC of TPGS <sub>2k</sub>	484
23.3.2 In vitro Drug Release	484
23.3.3 In vitro Cellular Uptake of Micelles	486
23.3.4 In vitro Cytotoxicity	489
23.4 Conclusions	492
 <b>24 Targeted Delivery of Paclitaxel Using Folate-Decorated Poly(Lactide)—Vitamin E TPGS Nanoparticles</b>	 <b>497</b>
<i>Jie Pan and Si-Shen Feng</i>	
24.1 Introduction	497
24.2 Materials and Methods	499
24.2.1 Materials	499
24.2.2 Synthesis and Characterization of PLA-TPGS Copolymer	499
24.2.3 Synthesis of TPGS-COOH and FOL-NH <sub>2</sub>	500
24.2.4 Formulation of Paclitaxel-Loaded NPs with Folate-Decoration	500
24.2.5 Characterization of Paclitaxel-Loaded NPs with Folate Decoration	501
24.2.5.1 Particle size and size distribution	501

24.2.5.2	Surface charge	501
24.2.5.3	Surface morphology	501
24.2.5.4	Drug encapsulation efficiency	501
24.2.6	Surface Chemistry	503
24.2.7	In vitro Drug Release Kinetics	503
24.2.8	Cell Cultures	503
24.2.9	In vitro Cellular Uptake of NPs	503
24.2.10	In vitro Cytotoxicity	504
24.3	Results and Discussion	505
24.3.1	Characterization of PLA-TPGS Copolymers	505
24.3.2	Characterization of Folate-Decorated NPs	505
24.3.2.1	Size and size distribution	505
24.3.2.2	Surface charge	506
24.3.2.3	Surface morphology	507
24.3.2.4	Drug encapsulation efficiency	507
24.3.3	Surface Chemistry	508
24.3.4	In vitro Drug Release	508
24.3.5	In vitro Cellular Uptake of NPs	509
24.3.6	In vitro Cytotoxicity	511
24.4	Conclusion	513

## PART VI CHEMOTHERAPEUTIC ENGINEERING: MULTIFUNCTIONAL NANOPARTICLES

<b>25</b>	<b>Multifunctional Nanoparticles of Biodegradable Copolymer Blend for Cancer Diagnosis and Treatment</b>	<b>521</b>
	<i>Jie Pan, Yutao Liu, and Si-Shen Feng</i>	
25.1	Materials and Methods	523
25.1.1	Materials	523
25.1.2	Synthesis of TPGS-COOH	524
25.1.3	Synthesis of FOL-NH <sub>2</sub>	524
25.1.4	Preparation of QD/Docetaxel-Loaded PLGA/TPGS-COOH NPs	524
25.1.5	Formulation of FOL-Conjugated QD/Docetaxel-Loaded PLGA/TPGS-COOH NPs	524
25.1.6	Characterization of TC NPs and FD NPs Particle Size and Size Distribution	525
25.1.6.1	Drug encapsulation and loading efficiency	526
25.1.6.2	Surface charge	526
25.1.6.3	Surface morphology	526
25.1.6.4	Surface chemistry	526
25.1.7	In vitro Drug Release	527
25.1.8	Photophysical Characterization Fluorescent Images	527
25.1.8.1	Emission spectra	527

25.1.9	QD Encapsulation and Loading Efficiency	527
25.1.10	Cell Line Experiment Cell Culture	528
25.1.10.1	In vitro Cellular Uptake of NPs	528
25.1.10.2	In vitro Therapeutic Effect and Targeting Effects	529
25.2	Results and Discussion	529
25.2.1	Characterization of QD/Docetaxel-Loaded NPs	
	Particle Size and Size Distribution	529
25.2.1.1	Drug encapsulation and loading efficiency	529
25.2.1.2	Surface charge	531
25.2.1.3	Surface morphology	531
25.2.1.4	Surface chemistry	531
25.2.1.5	In vitro drug release	531
25.2.2	Photophysical Characterization of FD NPs	533
25.2.2.1	Fluorescent images	533
25.2.2.2	Emission spectra	533
25.2.2.3	QD encapsulation and loading efficiency	534
25.2.3	In vitro Evaluation	534
25.2.3.1	In vitro cellular uptake of NPs	534
25.2.3.2	In vitro cytotoxicity	537
25.3	Conclusion	539
<b>26</b>	<b>Targeting and Imaging Cancer Cells by Folate-Decorated, Quantum Dots-Loaded Nanoparticles of Biodegradable Polymers</b>	<b>547</b>
	<i>Jie Pan and Si-Shen Feng</i>	
26.1	Introduction	547
26.2	Materials and Methods	550
26.2.1	Materials	550
26.2.2	Synthesis of TPGS-COOH and Folate-NH <sub>2</sub>	550
26.2.3	Formulation of QDs-Loaded NPs with Folate Decoration and Free QDs	551
26.2.4	Characterization of QDs-Loaded NPs with Folate Decoration	553
26.2.4.1	Particle size and size distribution	553
26.2.4.2	Surface charge	553
26.2.4.3	Surface morphology	553
26.2.4.4	Emission spectrum	553
26.2.4.5	QDs encapsulation efficiency	553
26.2.5	Surface Chemistry	554
26.2.6	Cell Line Experiment	554
26.2.6.1	Cell cultures	554
26.2.6.2	In vitro cellular uptake of NPs	554

26.2.6.3	In vitro cytotoxicity	555
26.3	Results and Discussion	555
26.3.1	Characterization of QDs-Loaded NPs with Folate Decoration	555
26.3.1.1	Size and size distribution	555
26.3.1.2	Surface charge	555
26.3.1.3	Surface morphology	556
26.3.1.4	Emission spectrum	556
26.3.1.5	QDs encapsulation efficiency	556
26.3.2	Surface Chemistry	557
26.3.3	In vitro cellular uptake of NPs	557
26.3.4	In vitro cytotoxicity	558
26.4	Conclusion	562
<b>27</b>	<b>Multifunctional Poly(D,L-Lactide-co-Glycolide)/Montmorillonite (PLGA/MMT) Nanoparticles Decorated by Trastuzumab for Targeted Chemotherapy of Breast Cancer</b>	<b>567</b>
	<i>Bingfeng Sun, Balu Ranganathan, and Si-Shen Feng</i>	
27.1	Introduction	567
27.2	Materials and Methods	570
27.2.1	Materials	570
27.2.2	Preparation of Nanoparticles	570
27.2.3	Characterization of NPs	570
27.2.3.1	Particle size and size distribution	570
27.2.3.2	Surface morphology	571
27.2.3.3	Surface charge	571
27.2.3.4	Drug encapsulation efficiency	571
27.2.3.5	Thermal gravimetric analysis	571
27.2.4	Surface Chemistry Analysis	571
27.2.5	SDS-PAGE Analysis	572
27.2.6	In vitro Drug Release Kinetics	572
27.2.7	Cell Cultures	572
27.2.8	In vitro Cellular Uptake of NPs	573
27.2.9	In vitro Cytotoxicity	573
27.3	Results and Discussions	574
27.3.1	Size, Size Distribution and Drug Encapsulation Efficiency	574
27.3.2	Surface Morphology	574
27.3.3	Surface Charge	576
27.3.4	Surface Chemistry	576
27.3.5	Stability of HER2 Antibody	576
27.3.6	Thermal Gravimetric Analysis	577

27.3.7	In vitro Drug Release	578
27.3.8	Cellular Uptake of Nanoparticles	578
27.3.9	Confocal Microscopy	583
27.3.10	In vitro Cytotoxicity	583
27.4	Conclusion	587

## PART VII CHEMOTHERAPEUTIC ENGINEERING: PRODRUGS

<b>28</b>	<b>Doxorubicin Conjugated to D-<math>\alpha</math>-Tocopheryl Polyethylene Glycol Succinate and Folic Acid as a Prodrug for Targeted Chemotherapy</b>	<b>595</b>
	<i>Vanangamudi Anbharasi, Na Cao, and Si-Shen Feng</i>	
28.1	Introduction	595
28.2	Materials and Methods	598
28.2.1	Materials	598
28.2.2	Preparation of Succinoylated TPGS	598
28.2.3	Synthesis of TPGS-DOX	598
28.2.4	Synthesis of Folate-Hydrazide	599
28.2.5	Synthesis of TPGS-DOX-FOL Conjugate	600
28.2.6	Characterization of DOX-TPGS-FOL Conjugate	600
28.2.7	In vitro Release of DOX from the conjugates	601
28.2.8	Cell Culture	602
28.2.9	In vitro Cellular Uptake of TPGS-DOX and TPGS-DOX-FOL Conjugates	602
28.2.10	Confocal Laser Scanning Microscopy	602
28.2.11	In vitro Cytotoxicity	603
28.2.12	In vivo Pharmacokinetics	603
28.2.13	In vivo Biodistribution	604
28.2.14	Statistical Analysis	604
28.3	Results and Discussion	604
28.3.1	Characterization	604
28.3.2	In vitro Drug Release	607
28.3.3	In vitro Cellular Uptake	608
28.3.4	Confocal Laser Scanning Microscopy	609
28.3.5	In vitro Cytotoxicity	611
28.3.6	In vivo Pharmacokinetics	612
28.3.7	In vivo Biodistribution	614
28.4	Conclusions	616
<b>29</b>	<b>Doxorubicin Conjugated to D-<math>\alpha</math>-Tocopheryl Polyethylene Glycol 1000 Succinate (TPGS): Conjugation Chemistry, Characterization, in vitro and in vivo Evaluation</b>	<b>623</b>
	<i>Na Cao and Si-Shen Feng</i>	
29.1	Introduction	623



29.2	Materials and Methods	625
29.2.1	Materials	625
29.2.2	Preparation of Succinoylated TPGS	625
29.2.3	Conjugation of Doxorubicin to TPGS	626
29.2.4	Characterization of TPGS–DOX Conjugate	626
29.2.5	In vitro Release of DOX from the Conjugate	626
29.2.6	Cell Culture	627
29.2.7	In vitro Cell Uptake of TPGS–DOX Conjugate	627
29.2.8	Confocal Laser Scanning Microscopy	627
29.2.9	In vitro Cytotoxicity	627
29.2.10	In vivo Pharmacokinetics	629
29.2.11	Biodistribution	629
29.2.12	Statistics	630
29.3	Results	630
29.3.1	Characterization of TPGS–DOX Conjugate	630
29.3.2	In vitro Release of DOX from the Conjugate	631
29.3.3	In vitro Cell Uptake of the Conjugate	632
29.3.4	In vitro Cytotoxicity	633
29.3.5	In vivo Pharmacokinetics	637
29.3.6	Biodistribution	638
29.4	Discussion	640
29.5	Conclusions	642

## PART VIII CHEMOTHERAPEUTIC ENGINEERING: ORAL CHEMOTHERAPY

<b>30</b>	<b>Nanothermotherapy by High Performance Magnetic Nanoparticles</b>	<b>649</b>
	<i>Lingyun Zhao, Jintian Tang, and Si-Shen Feng</i>	
<b>31</b>	<b>Poly(Lactide)-Vitamin E Derivative/Montmorillonite Nanoparticle Formulations for the Oral Delivery of Docetaxel</b>	<b>655</b>
	<i>Si-Shen Feng, Lin Mei, Panneerselvan Anitha, Chee Wee Gan, and Wenyou Zhou</i>	
31.1	Introduction	655
31.2	Materials and Methods	658
31.2.1	Materials	658
31.2.2	Synthesis and Characterization of PLA–TPGS Copolymers	658
31.2.3	Preparation of Docetaxel- or Coumarin 6-Loaded NPs	658
31.2.4	Characterization of Drug-Loaded NPs	659
	31.2.4.1 Size and zeta potential	659
	31.2.4.2 Surface morphology	659
	31.2.4.3 Drug encapsulation efficiency	659
	31.2.4.4 MMT content analysis by TGA	660

31.2.4.5	Physical status of Docetaxel and MMT in the NPs	660
31.2.4.6	In vitro drug release	660
31.2.5	Cell Culture	661
31.2.5.1	Caco-2 and MCF-7 cell uptake of fluorescent NPs	661
31.2.5.2	Confocal laser scanning microscopy	661
31.2.5.3	In vitro cytotoxicity of Docetaxel-loaded NPs	661
31.2.6	In vivo Pharmacokinetics	662
31.3	Results and Discussions	663
31.3.1	Characterization of PLA-TPGS Copolymer	663
31.3.2	Characterization of Drug-Loaded NPs	663
31.3.2.1	Size, zeta potential, MMT content, and drug encapsulation efficiency	663
31.3.2.2	Surface morphology	665
31.3.2.3	Physical status of Docetaxel and MMT in the nanoparticles	666
31.3.2.4	In vitro drug release	666
31.3.3	Uptake of Coumarin 6-Loaded NPs by Caco-2 and MCF-7 Cells	667
31.3.4	Confocal Laser Scanning Microscopy	670
31.3.5	In vitro Cell Viability of NPs	671
31.3.6	In vivo Pharmacokinetics	671
31.4	Conclusion	675
<b>32</b>	<b>Enhanced Oral Bioavailability of Paclitaxel Formulated in Vitamin E-TPGS Emulsified Nanoparticles of Biodegradable Polymers: in vitro and in vivo Studies</b>	<b>681</b>
	<i>Lingyun Zhao and Si-Shen Feng</i>	
32.1	Introduction	681
32.2	Experimental	683
32.2.1	Materials	683
32.2.2	Preparation and Characterization of NPs	684
32.2.3	In vitro Cytotoxicity	685
32.2.4	In vivo Pharmacokinetics	685
32.2.5	HPLC Assay	686
32.2.6	Statistical Analysis	686
32.3	Results and Discussion	686
32.3.1	NPs Size, Surface Morphology, and Surface Charge	686
32.3.2	In vitro Drug Release Profile	687
32.3.3	In vitro Cytotoxicity	690
32.3.4	Oral Unavailability	692
32.4	Conclusion	695

<b>33 Self-Assembled Nanoparticles of Poly(Lactide)-Vitamin E TPGS Copolymers for Oral Chemotherapy</b>	<b>699</b>
<i>Zhiping Zhang and Si-Shen Feng</i>	
33.1 Introduction	699
33.2 Materials and Methods	701
33.2.1 Materials	701
33.2.2 Preparation of Paclitaxel-Loaded PLA-TPGS Nanoparticles	701
33.2.3 Characterization of Nanoparticles	702
33.2.3.1 Particle size and surface morphology	702
33.2.3.2 Drug encapsulation efficiency	702
33.2.3.3 DSC analysis	702
33.2.3.4 In vitro drug release	702
33.2.4 Cell Line Experiment	703
33.2.4.1 Cell culture	703
33.2.4.2 In vitro cellular uptake of nanoparticles	703
33.2.4.3 In vitro cytotoxicity of paclitaxel-loaded nanoparticles	704
33.2.5 Statistical Analysis	704
33.3 Results and Discussion	704
33.3.1 Physicochemical Properties of Nanoparticles	704
33.3.1.1 Size, size distribution, and drug encapsulation efficiency	704
33.3.1.2 Surface morphology of nanoparticles	705
33.3.1.3 DSC analysis	705
33.3.2 In vitro Investigation	705
33.3.2.1 In vitro drug release	705
33.3.2.2 Cellular uptake of nanoparticles	706
33.3.2.3 Cytotoxicity of nanoparticles	709
33.4 Conclusion	710
 <b>34 Effects of Particle Size and Surface Coating on Cellular Uptake of Polymeric Nanoparticles for Oral Delivery of Anticancer Drugs</b>	 <b>715</b>
<i>Khin Yin Win and Si-Shen Feng</i>	
34.1 Introduction	715
34.2 Experimental Methods	717
34.2.1 Materials	717
34.2.2 Preparation of Nanoparticles	717
34.2.3 Characterization of Nanoparticles	718
34.2.3.1 Size and size distribution	718
34.2.3.2 Surface morphology	718
34.2.3.3 Surface charge	719

34.2.4	In vitro Release of Fluorescent Markers from Nanoparticles	719
34.2.5	Cell Culture	719
34.2.6	Nanoparticle Uptake by Caco-2 Cells	719
34.2.6.1	Quantitative studies	719
34.2.6.2	Qualitative studies	720
34.3	Results and Discussion	721
34.3.1	Physicochemical Properties of Nanoparticles	721
34.3.1.1	Size and size distribution	721
34.3.1.2	Morphology of nanoparticles	721
34.3.1.3	Surface charge of nanoparticles	722
34.3.1.4	In vitro fluorescent marker release	722
34.3.2	Cell Uptake of Nanoparticles	723
34.3.2.1	Effect of particle surface coating, incubation time and temperature	723
34.3.2.2	Effect of particle size and concentration	725
34.3.2.3	Confocal microscopy	727
34.3.2.4	Cryo-SEM and TEM	729
34.4	Conclusions	730
<b>35</b>	<b>Poly(D,L-Lactide-co-Glycolide)/ Montmorillonite Nanoparticles for Oral Delivery of Anticancer Drugs</b>	<b>735</b>
	<i>Yuancai Dong and Si-Shen Feng</i>	
35.1	Introduction	735
35.2	Materials and Methods	737
35.2.1	Materials	737
35.2.2	Preparation of Paclitaxel-Loaded or Coumarin 6-Loaded PLGA/MMT Nanoparticles	737
35.2.3	Size and Zeta Potential	738
35.2.4	Drug Encapsulation Efficiency	738
35.2.5	MMT Content Analysis by TGA	738
35.2.6	Morphology	738
35.2.7	In vitro Drug Release	739
35.2.8	Physical Status of Paclitaxel and MMT	739
35.2.9	Caco-2 and HT-29 Cell Uptake of Nanoparticles	739
35.2.10	Confocal Laser Scanning Microscopy	740
35.3	Results and Discussion	740
35.3.1	Size, Zeta Potential, MMT Content, and Drug Encapsulation Efficiency	740
35.3.2	Surface Morphology	742
35.3.3	In vitro Drug Release	742
35.3.4	Physical Status of Paclitaxel and MMT in the Nanoparticles	744

35.3.5	Uptake of Coumarin 6-Loaded PLGA/MMT Nanoparticles by Caco-2 and HT-29 Cells	744
35.3.6	Confocal Laser Scanning Microscopy	748
35.4	Conclusions	748

## PART IX CHEMOTHERAPEUTIC ENGINEERING: DRUG DELIVERY ACROSS THE BLOOD–BRAIN BARRIER

<b>36</b>	<b>Effects of Surface Modification on Delivery Efficiency of Biodegradable Nanoparticles across the Blood–Brain Barrier</b>	<b>755</b>
	<i>Sneha Avinash Kulkarni and Si-Shen Feng</i>	
36.1	Materials and Methods	758
36.1.1	Materials	758
36.1.2	Preparation of NPs	758
36.1.3	Characterization of NPs Size and Size Distribution	759
36.1.3.1	Surface Charge	759
36.1.3.2	Surface Morphology	759
36.1.3.3	Encapsulation Efficiency	760
36.1.3.4	In vitro Release	760
36.1.4	Cell Culture	760
36.1.5	In vitro Cellular Uptake of NPs Qualitative Study: Confocal Laser Scanning Microscopic	760
36.1.5.1	Quantitative Study: Cellular Uptake	761
36.1.5.2	In vitro Cell Cytotoxicity	761
36.1.6	In vivo Study	762
36.1.7	Tissue Preparation	763
36.2	Results and Discussion	763
36.2.1	NPs Characterization Size and Size Distribution	763
36.2.1.1	Surface charge	764
36.2.1.2	Surface morphology	765
36.2.1.3	Encapsulation efficiency (%)	765
36.2.1.4	In vitro release	766
36.2.2	Cellular Uptake Efficiency: MDCK Cells	767
36.2.2.1	Qualitative and quantitative study	767
36.2.3	In vivo Analysis	770
36.2.3.1	Biodistribution	770
36.2.3.2	Fluorescence microscopic analysis of brain	773
36.2.4	In vitro Cytotoxicity	773
36.3	Conclusion	777
36.4	Future Perspective	778

<b>37 Transferrin-Conjugated Nanoparticles of Poly(Lactide)-D-<math>\alpha</math>-Tocopheryl Polyethylene Glycol Succinate Diblock Copolymer for Targeted Drug Delivery across the Blood–Brain Barrier</b>	<b>785</b>
<i>Chee Wee Gan and Si-Shen Feng</i>	
37.1 Introduction	785
37.2 Materials and Methods	788
37.2.1 Materials	788
37.2.2 Methods	789
37.2.2.1 Preparation of nanoparticles	789
37.2.2.2 Surface modification of nanoparticles with human transferrin	789
37.2.2.3 Particle size and surface morphology	789
37.2.2.4 Surface charge and surface chemistry	790
37.2.2.5 Drug encapsulation efficiency	790
37.2.2.6 Cellular uptake	790
37.2.2.7 Ex vivo biodistribution of nanoparticles	791
37.2.2.8 Cytotoxicity of the nanoparticles formulations	792
37.2.3 Statistical Analysis	793
37.3 Results and Discussion	793
37.3.1 Nanoparticle Formulations	793
37.3.2 Cellular Uptake	796
37.3.2.1 Confocal laser scanning microscopy	796
37.3.2.2 96-well plates technique	797
37.3.3 Ex vivo Biodistribution of Nanoparticles	798
37.3.4 Cytotoxicity of Nanoparticles Formulations	801
37.4 Conclusion	803

## **PART X CHEMOTHERAPEUTIC ENGINEERING: MULTIMODAL IMAGING**

<b>38 Nanotechnology for Multimodal Imaging</b>	<b>811</b>
<i>Yutao Liu, Yu Mi, and Si-Shen Feng</i>	
<b>39 Multimodal Tumor Imaging by Iron Oxides and QDs Formulated in PLA-TPGS Nanoparticles</b>	<b>819</b>
<i>Yang Fei Tan, Prashant Chandrasekharan, Dipak Maity, Cai Xian Yong, Kai-Hsiang Chuang, Ying Zhao, Shu Wang, Jun Ding, and Si-Shen Feng</i>	
39.1 Introduction	819
39.2 Materials and Methods	822
39.2.1 Materials	822
39.2.2 Flocculation of QDs	822
39.2.3 Formulation of QDs and IOs-Loaded NPs	823

39.2.4	Characterization of QDs and IOs-Loaded NPs	823
39.2.4.1	Particle size and size distribution	823
39.2.4.2	Surface charge	823
39.2.4.3	TEM analysis	823
39.2.4.4	QDs and IOs encapsulation efficiency	824
39.2.5	Cell Line Experiment	824
39.2.5.1	Cell cultures	824
39.2.5.2	In vitro cellular uptake of NPs	824
39.2.5.3	In vitro cytotoxicity	825
39.2.6	Animal Study	825
39.2.6.1	Tumor Imaging	826
39.2.6.2	Tumor imaging (fluorescent imaging)	826
39.2.6.3	Biodistribution	826
39.3	Results and Discussion	827
39.3.1	Characterization of QDs and IOs-Loaded Nanoparticles	827
39.3.1.1	Size and size distribution	827
39.3.1.2	Surface charge	827
39.3.1.3	TEM analysis	827
39.3.1.4	QDs and IO encapsulation efficiency	828
39.3.2	Cell Line Experiment	828
39.3.2.1	In vitro cellular uptake of NPs	828
39.3.2.2	In vitro cytotoxicity	830
39.3.3	Animal Study	831
39.4	Conclusion	837
<b>40</b>	<b>Vitamin E (D-Alpha-Tocopheryl-co-Poly(Ethylene Glycol) 1000 Succinate) Micelles-Superparamagnetic Iron Oxide Nanoparticles for Enhanced Thermotherapy and MRI</b>	<b>841</b>
	<i>Prashant Chandrasekharan, Dipak Maity, Cai Xian Yong, Kai-Hsiang Chuang, Jun Ding, and Si-Shen Feng</i>	
40.1	Introduction	841
40.2	Materials and Methods	843
40.2.1	Materials	843
40.2.2	Synthesis and Characterization of IOs-Loaded Micelles	844
40.2.3	ICP-MS Analysis	844
40.2.4	Hysteresis	844
40.2.5	Cell Viability Assay	844
40.2.6	Determination of SAR Value and Cell Hyperthermia	845
40.2.7	Quantitative and Qualitative Cell Uptake Study	846
40.2.8	Magnetic Resonance Properties and in vivo MRI	846

40.2.8.1	Calculation of relaxivity	847
40.2.8.2	Xenograft model and in vivo MRI	847
40.3	Results and Discussion	847
40.3.1	Characterization of Magnetic Micelles	847
40.3.2	Magnetic Property	849
40.3.3	Cell Viability	851
40.3.4	Magnetic Hyperthermia	852
40.3.5	Cellular Uptake	854
40.3.6	MRI	855
40.4	Conclusion	858
<b>41</b>	<b>Superparamagnetic Iron Oxide—Loaded Poly(Lactic Acid)-D-<math>\alpha</math>-Tocopherol Polyethylene Glycol 1000 Succinate Copolymer Nanoparticles as MRI Contrast Agent</b>	<b>863</b>
	<i>Chandrasekharan Prashant, Maity Dipak, Chang-Tong Yang, Kai-Hsiang Chuang, Ding Jun, and Si-Shen Feng</i>	
41.1	Introduction	863
41.2	Materials and Methods	866
41.2.1	Materials	866
41.2.2	Synthesis of PLA-TPGS polymer	866
41.2.3	Synthesis of IOs	866
41.2.4	Preparation of IOs-Encapsulated Polymeric Nanoparticles	867
41.2.5	X-Ray Photoelectron Spectroscopy	867
41.2.6	ICP-MS Analysis	867
41.2.7	Magnetic Property of IOs-PNPs	868
41.2.8	In vitro Cytotoxicity	868
41.2.9	In vitro Cellular Uptake of NPs	868
41.2.9.1	Quantitative evaluation	868
41.2.9.2	Qualitative analysis	869
41.2.10	MRI	869
41.2.10.1	Calculation of relaxivity	869
41.2.10.2	In vivo MRI study	869
41.3	Results and Discussion	870
41.3.1	Synthesis of PLA-TPGS Copolymer	870
41.3.2	Synthesis of Hydrophobic IOs	871
41.3.3	Synthesis of IOs-Encapsulated Polymeric Nanoparticles	871
41.3.4	XPS Analysis	875
41.3.5	Hysteresis	876
41.3.6	Cytotoxicity	877
41.3.7	Cellular Uptake of IOs-PNPs	878



41.3.7.1	Quantitative investigation	878
41.3.7.2	Qualitative investigation	878
41.3.8	In vivo MRI	880
41.3.8.1	Relaxivity studies	880
41.3.8.2	In vivo liver clearance	880
41.3.8.3	In vivo tumor MRI	881
41.4	Conclusion	882
<b>42</b>	<b>Formulation, Characterization, and in vitro Evaluation of Quantum Dots Loaded in Poly(Lactide)-Vitamin E TPGS Nanoparticles for Cellular and Molecular Imaging</b>	<b>887</b>
	<i>Jie Pan, Yan Wang, and Si-Shen Feng</i>	
42.1	Introduction	887
42.2	Materials and Methods	891
42.2.1	Materials	891
42.2.2	Synthesis of PLA-TPGS Copolymer	891
42.2.3	Preparation of QDs-Loaded PLA-TPGS NPs and MAA-Coated QDs	891
42.2.4	Characterization of QDs-Loaded PLA-TPGS NPs	892
42.2.4.1	Particle size analysis	892
42.2.4.2	Surface morphology	892
42.2.4.3	Surface chemistry of QDs-loaded PLA-TPGS NPs	893
42.2.5	Photophysical Characterization	893
42.2.5.1	Fluorescent images	893
42.2.5.2	Emission Spectra	893
42.2.5.3	The photostability	893
42.2.6	QDs Encapsulation Efficiency	894
42.2.7	Cell Line Experiment	894
42.2.7.1	Cell culture	894
42.2.7.2	In vitro cellular uptake of QDs-loaded PLA-TPGS NPs	894
42.2.7.3	In vitro cytotoxicity of QDs-loaded PLA-TPGS NPs	895
42.3	Results and Discussion	895
42.3.1	Characterization of the PLA-TPGS Copolymer	895
42.3.2	Characterization of QDs-Loaded PLA-TPGS NPs	895
42.3.2.1	Size and size distribution	895
42.3.2.2	Surface morphology	896
42.3.2.3	Surface chemistry of QDs-loaded PLA-TPGS NPs	897
42.3.3	Photophysical Characterization	899

42.3.3.1	Fluorescent colors and emission spectra	899
42.3.3.2	Photostability	901
42.3.4	QDs Encapsulation Efficiency	902
42.3.5	In vitro Evaluation	902
42.3.5.1	Cellular uptake of nanoparticles	902
42.3.5.2	In vitro cytotoxicity of QDs-loaded PLA-TPGS NPs	903
42.4	Conclusion	905
<b>43</b>	<b>Formulation of Superparamagnetic Iron Oxides by Nanoparticles of Biodegradable Polymers for Magnetic Resonance Imaging</b>	<b>911</b>
	<i>Yan Wang, Yee Woon Ng, Yan Chen, Borys Shuter, Jiabao Yi, Jun Ding, Shih-chang Wang, and Si-Shen Feng</i>	
43.1	Introduction	911
43.2	Results and Discussion	914
43.2.1	Physicochemical Characteristics of IO-loaded PLGA-mPEG NPs	914
43.2.1.1	Particle size and iron loading	914
43.2.1.2	Surface morphology	916
43.2.1.3	X-ray diffraction and X-ray photoelectron spectroscopy analyses	917
43.2.1.4	Stability	917
43.2.1.5	In vitro release profile	918
43.2.2	Magnetic Properties	919
43.2.2.1	Superparamagnetic properties	919
43.2.2.2	Saturation magnetization and blocking temperature	920
43.2.3	MR Characteristics	923
43.2.3.1	In vitro relaxivities	923
43.2.3.2	Possible effects of PLGA-mPEG copolymers	925
43.2.4	In vitro Cytotoxicity	925
43.2.5	In vitro and ex vivo MRI	927
43.2.5.1	In vitro MRI	927
43.2.5.2	Ex vivo MRI	928
43.3	Conclusions	929
43.4	Experimental	929
43.4.1	Materials	929
43.4.2	Nanoparticle Formulation of IOs	930
43.4.3	Physicochemical Characterization of IO-Loaded NPs	930
43.4.3.1	Particle size analysis	930
43.4.3.2	Transmission electron microscopy	930
43.4.3.3	Surface morphology	930

43.4.3.4	Stability studies	931
43.4.3.5	In vitro IO release	931
43.4.3.6	XRD and XPS	931
43.4.3.7	ICP-MS	931
43.4.3.8	Saturation magnetization measurements	932
43.4.4	In vitro Cytotoxicity	932
43.4.5	MRI Characterization	932
43.4.5.1	In vitro MRI	932
43.4.5.2	Ex vivo MRI	933

## PART XI MOLECULAR BIOMATERIALS FOR NANOMEDICINE

<b>44</b>	<b>Vitamin E TPGS as a Molecular Biomaterial for Drug Delivery</b>	<b>939</b>
	<i>Zhiping Zhang, Songwei Tan, and Si-Shen Feng</i>	
44.1	Introduction	939
44.2	TPGS as Prodrug Carrier	941
44.2.1	TPGS-DOX Conjugate	942
44.2.2	TPGS-Paditaxel Conjugate	943
44.3	TPGS-Based Micelles	944
44.4	TPGS-Based Liposomes	946
44.5	TPGS-Emulsified Nanoparticles	947
44.5.1	TPGS-Emulsified PLGA NP for i.v. Administration	947
44.5.2	TPGS-Emulsified PLGA Nanoparticles for Oral Delivery	949
44.5.3	TPGS-Emulsified PLGA NP and Further Coated with Tween 80 for Delivery to Cross BBB	950
44.5.4	TPGS-Emulsified Nanoparticles for Cardiovascular Restenosis Treatment	950
44.6	TPGS as Additive for Nanoparticles Formulation	951
44.7	Biodegradable PLA-TPGS Copolymers in Drug Delivery	951
44.7.1	Polymer Synthesis	951
44.7.2	Nanopartides Fabrication	953
44.7.2.1	Nanoprecipitation method	953
44.7.2.2	Solvent extraction/evaporation (single emulsion) method	953
44.7.2.3	Dialysis method	954
44.7.2.4	Double emulsion method	955
44.7.3	Drug or Imaging Agent Encapsulation	955
44.7.3.1	Docetaxel	955
44.7.3.2	Paditaxel	960
44.7.3.3	Doxorubicin	961
44.7.3.4	Curcumin and risperidone	962
44.7.3.5	Protein delivery	962
44.7.3.6	Supraparamagnetic iron oxides	963

44.7.3.7	Quantum dots	963
44.7.3.8	Multimodal imaging system	964
44.8	Targeting Strategies	967
44.8.1	TPGS-FOL Conjugate	967
44.8.2	TPGS-COOH	968
44.8.3	Antibody Coated on the Surface of Nanoparticles	971
44.9	Advantages of the PLA-TPGS Series Copolymer	971
<i>Index</i>		983



## Preface

Cancer is a leading cause of death worldwide and has become the number one killer in many countries, including China and Singapore. It was responsible for approximately 23.1%, 23.2%, 23.1%, 23.4%, and 23.3% of disease mortality from 2006 to 2010 in the United States and 27.7%, 29.3%, 29.3%, 28.5%, and 30.0% from 2007 to 2011 in Singapore, respectively. The World Health Organization estimates that global cancer rates could increase by 50% to 15 million patients and cancer rates in Asia could increase by 60% to 7.1 million patients by 2020. In spite of such a serious situation, no substantial progress in fighting cancer could be observed before the end of the past century. The cancer death rate in the United States was 1.939‰ of the total population in 1950 and still remained 1.940‰ in 2001. Beyond these staggeringly dismal numbers, however, recent statistics have found that the cancer survival rate is slightly increasing for the first time in the first decade of the 21st century, which led to a slight decrease in the cancer death rate to 1.901‰ in 2003, 178.4‰ in 2007 and 172.8‰ in 2010 in the United States. This may have largely resulted from the significant achievements in cellular and molecular biology, from which new knowledge of cancer has been acquired and new diagnostic and therapeutic techniques could thus be developed. The US National Cancer Institute, the National Institutes of Health, and the US Department of Health and Human Services jointly published a white paper on cancer nanotechnology in 2004, which predicted that cancer nanotechnology will radically change the way we diagnose, treat, and prevent cancer (<http://www.nci.org>).

Chemotherapy is often related to cancer treatment. Nevertheless, a more general definition of chemotherapy could mean “curing disease by drugs” or as given by Dr. Paul Ehrlich, the father of modern chemotherapy, “curing by chemicals.” With recent achievements in cellular and molecular biology, drugs can now also include biologically active macromolecules such as proteins and peptides. Chemotherapy is, thus, involved in the entire internal medicine. Chemotherapy is a complicated procedure in which many factors are involved in determining its success or failure. It carries a high risk due to drug toxicity, and the more effective drugs tend to be more toxic; its unfavorable pharmacokinetics and biodistribution are also a concern. Even successful chemotherapy is associated with problems. The patients have to tolerate severe side effects and

sacrifice their quality of life. Chemotherapy should become more important and more effective if its problems in pharmacokinetics and pharmacodynamics could be solved, which include the toxicity of the drugs; drug targeting; drug adsorption, distribution, metabolism, and excretion (ADME); drug resistance at various physiological levels from organs such as the first pass by the liver and the kidneys to cellular and molecular levels such as the various physiological drug barriers, including the gastrointestinal (GI) barrier and the blood–brain barrier (BBB). The problems could be solved by adopting two kinds of approaches: medical solution and engineering solution. The former is to use other drug or drugs to overcome the complications caused by the prescribed one. A typical example is the co-administration of cyclosporine A, a P-gp/P450 inhibitor, to make paclitaxel orally bioavailable, i.e., deliverable into the blood system through the oral route. However, cyclosporine A suppresses the body immune system and thus may cause severe side effects. Moreover, cyclosporine A has its own difficulty in formulation. It is clear that such medical approach is not a preferable solution. The engineering solution is to modify the molecular structure of the drug or to formulate the drug in various nanoscale carriers such as prodrugs, micelles, liposomes, dendrimers, nanohydrogels, and biodegradable nanoparticles, i.e., “to engineering the drugs” for delivery, which, in this case, can bring the drug across the GI barrier. Drugs formulated in the various nanoscale carriers for sustained, controlled, and targeted delivery are also called nanomedicine. Si-Shen Feng at the National University of Singapore, under the advice of Prof. Shu Chien at the University of California, San Diego, recognized the challenge by applying engineering, especially chemical engineering principles, to solve the problems in chemotherapy and defined the strategy as chemotherapeutic engineering in 2003. He believes that together with tissue engineering, which will revolutionize the concept of surgery from “cut and throw the diseased tissue or organ” to “repair and replace them by biologically engineered tissue or organ,” chemotherapeutic engineering will contribute towards the 21st-century medicine.

This book is the collection of the peer-reviewed scientific and technological articles published from 2003 to 2012 by Prof. Si-Shen Feng, which are closely relevant to chemotherapeutic engineering. The collection comprises contributions ranging from founding articles to proof-of-concept experimental reports and covers the synthesis of novel molecular biomaterials design and preparation of drug carriers at the nanoscale, ligand conjugation for targeting, the characterization of the drug-loaded nanocarriers, in vitro cellular uptake of nanocarriers and in vitro assessment of the cytotoxicity of the formulated drug, in vivo investigation on pharmacokinetics and biodistribution and the xenograft tumor model. Paclitaxel and docetaxel are used as model drugs owing to their role as the number one seller in the global market of anticancer drugs and great difficulties in their formulation for clinical application. The methodology is also

applicable for the formulation of imaging agents such as supraparamagnetic iron oxides for magnetic resonance imaging. Chemotherapeutic engineering is thus relevant to pharmaceutical nanotechnology in the pharmaceutical industry. Formulation and combined diagnostic and therapeutic agents are now called nanodiagnostics

This book provides necessary knowledge for scientists, engineers, and master's and PhD students who want to be well prepared to work in the fields of chemotherapeutic engineering, cancer nanotechnology, and nanomedicine, or more generally in biomedical engineering. It also provides the basic knowledge and models for people who work in cancer clinics as well as in the pharmaceutical industry. It can also be used as a textbook or a reference book in teaching of courses such as drug delivery, chemotherapeutic engineering, and overview of nanomedicine. In fact, most of the contributions in this book have been used in the undergraduate course Engineering Principles of Drug Delivery, which is given by Prof. Si-Shen Feng in the National University of Singapore since 2002.

The editors thank the Agency for Science, Technology and Research (A\*STAR) and the National University of Singapore (NUS) for financial support for the research conducted in the Chemotherapeutic Engineering Laboratory in the past decade. Prof. Feng sincerely acknowledges his postdoctoral fellows and PhD students. Among them, Drs. Li Mu, Lin Mei, M. S. Muthu, S. A. Kulkarni, Zhiping Zhang, K. Y. Win, Lingyun Zhao, Gang Ruan, Yuancai Dong, Jie Pan, P. Chandrasekharan, Bingfeng Sun, Yutao Liu, Yu Mi, and Jing Zhao made significant contributions in the various key steps. Finally, we would like to thank Mr. Arvind Kanswal of Pan Stanford Publishing for his commitment and assistance.

**Si-Shen Feng**  
**Stanford Chong**  
**Jenny Rompas**  
December 2013



